Hatime Arzu Yasar1,2, Kadriye Bir Yucel3, Cagatay Arslan4, Gokhan Ucar5, Serdar Karakaya6, Burak Bilgin7, Hakan Taban8, Ahmet Kucukarda9, Ismail Erturk10, Mutlu Hızal7, Birol Yıldız10, Nuriye Yıldırım7, Umut Demirci6, Mehmet Ali Sendur7, Gungor Utkan1,2, Saadettin Kılıckap8, Irfan Cicin9, Nuri Karadurmus10, Yüksel Ürün1,2. 1. Faculty of Medicine, Medical Oncology Department, Ankara University Ankara, Turkey. 2. Cancer Research Institute, Ankara University, Ankara, Turkey. 3. Faculty of Medicine, Internal Medicine Department, Ankara University, Ankara, Turkey. 4. Faculty of Medicine, Department of Internal Medicine and Medical Oncology, Bahcesehir University, Istanbul, Turkey. 5. Ankara Numune Education and Research Hospital, Medical Oncology Department, University of Health Sciences, Ankara, Turkey. 6. Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Medical Oncology Department, University of Health Sciences, Ankara, Turkey. 7. Faculty of Medicine, Medical Oncology Department, Ankara Yıldırım Beyazıt University, Ankara, Turkey. 8. Faculty of Medicine, Medical Oncology Department, Hacettepe University, Ankara, Turkey. 9. Faculty of Medicine, Department of Medical Oncology, Trakya University, Edirne, Turkey. 10. Gülhane Education and Research Hospital, Medical Oncology Department, University of Health Sciences, Ankara, Turkey.
Abstract
INTRODUCTION AND AIM: To investigate the effect of the prognostic nutritional index on treatment response and survival in patients with metastatic renal cell cancer. METHODS: We retrospectively analyzed the treatment modalities; the demographic, clinical and pathological features of 396 patients with RCC and prognostic nutritional index. Based on the median value, patients were grouped as having low and high prognostic nutritional index values. Kaplan-Meier method was used for survival analysis, and Cox-regression analysis was used for multivariate analysis. RESULTS: The median overall survival was 39 months (95% CI 26.1-51.8), 28 months (95% CI 17.9-38) and 7 months (95% CI 4.7-9.2) in patients with favorable, intermediate and poor International Metastatic Renal Cell Carcinoma Database Consortium risk group, respectively. The difference between the groups was statistically significant (p < 0001). Overall survival was 11 months (95% CI 7.5-14.5) in the low-prognostic nutritional index (prognostic nutritional index ≤38.5) group, and 41 months (95% CI 30.5-51.4) in the high prognostic nutritional index (prognostic nutritional index >38.5) group (p < 0.001). In Cox regression analysis, Eastern Cooperative Oncology Group performance score (HR: 2.5), time to systemic treatment (HR: 1.7) and prognostic nutritional index (HR: 1.8) were associated with overall survival. CONCLUSION: In patients with renal cell cancer, prognostic nutritional index is closely related to survival and has prognostic significance.
INTRODUCTION AND AIM: To investigate the effect of the prognostic nutritional index on treatment response and survival in patients with metastatic renal cell cancer. METHODS: We retrospectively analyzed the treatment modalities; the demographic, clinical and pathological features of 396 patients with RCC and prognostic nutritional index. Based on the median value, patients were grouped as having low and high prognostic nutritional index values. Kaplan-Meier method was used for survival analysis, and Cox-regression analysis was used for multivariate analysis. RESULTS: The median overall survival was 39 months (95% CI 26.1-51.8), 28 months (95% CI 17.9-38) and 7 months (95% CI 4.7-9.2) in patients with favorable, intermediate and poor International Metastatic Renal Cell Carcinoma Database Consortium risk group, respectively. The difference between the groups was statistically significant (p < 0001). Overall survival was 11 months (95% CI 7.5-14.5) in the low-prognostic nutritional index (prognostic nutritional index ≤38.5) group, and 41 months (95% CI 30.5-51.4) in the high prognostic nutritional index (prognostic nutritional index >38.5) group (p < 0.001). In Cox regression analysis, Eastern Cooperative Oncology Group performance score (HR: 2.5), time to systemic treatment (HR: 1.7) and prognostic nutritional index (HR: 1.8) were associated with overall survival. CONCLUSION: In patients with renal cell cancer, prognostic nutritional index is closely related to survival and has prognostic significance.